UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

β-arrestin2 is indispensable for the antidepressant effects of fluoxetine via inhibiting astrocytic pyroptosis in chronic mild stress mouse model for depression

European journal of pharmacology, 2024-08, Vol.976, p.176693, Article 176693

2024

Volltextzugriff (PDF)

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

The lancet oncology, 2022-02, Vol.23 (2), p.220-233

2022

Volltextzugriff (PDF)

Spatiotemporal reconstruction of global ocean surface pCO2 based on optimized random forest

The Science of the total environment, 2024-02, Vol.912, p.169209-169209, Article 169209

2024

Volltextzugriff (PDF)

A method for estimating particulate organic carbon at the sea surface based on geodetector and machine learning

Frontiers in Marine Science, 2023-12, Vol.10

2023

Volltextzugriff (PDF)

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

The lancet respiratory medicine, 2021-10, Vol.9 (10), p.1154-1164

2021

Volltextzugriff (PDF)

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2024-01, Vol.331 (3), p.201

2024

Volltextzugriff (PDF)

HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription Factor SP1, Potentiating BMP9-Induced Angiogenesis

Cells (Basel, Switzerland), 2024-03, Vol.13 (6), p.490

2024

Volltextzugriff (PDF)

Novel bismuth ferrite nanopowder prepared by polyethylene glycol-assisted two-step solid-state reaction: Synthesis and magneto-optical properties

Ceramics international, 2021-02, Vol.47 (3), p.3514-3519

2021

Volltextzugriff (PDF)

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9027-9027

2022

Volltextzugriff (PDF)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

JTO clinical and research reports, 2021-10, Vol.2 (10), p.100225-100225, Article 100225

2021

Volltextzugriff (PDF)

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Therapeutic advances in medical oncology, 2022, Vol.14, p.17588359221133546

2022

Volltextzugriff (PDF)

Spatiotemporal reconstruction of global ocean surface pCO 2 based on optimized random forest

The Science of the total environment, 2023-12, Vol.912, p.169209

2023

Volltextzugriff (PDF)

Enzymatic preparation of rice-starch-based surface-modified disordered carbon as an anode for lithium-ion batteries

Ionics, 2021, Vol.27 (1), p.59-64

2021

Volltextzugriff (PDF)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

JTO clinical and research reports, 2022-10, Vol.3 (10), p.100407-100407, Article 100407

2022

Volltextzugriff (PDF)

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Journal of thoracic oncology, 2022-10, Vol.17 (10), p.1192-1204

2022

Volltextzugriff (PDF)

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

Lung cancer (Amsterdam, Netherlands), 2024-09, Vol.195, p.107901, Article 107901

2024

Volltextzugriff (PDF)

Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations ( METex14 )

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT158-CT158

2021

Volltextzugriff (PDF)

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study

Lung cancer (Amsterdam, Netherlands), 2020-08, Vol.146, p.252-262

2020

Volltextzugriff (PDF)

Power Sequencial Data - Forecasting Trend

Multimedia Technology and Enhanced Learning, p.369-379

Volltextzugriff (PDF)

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

The lancet respiratory medicine, 2024-10, Vol.12 (10), p.775-786

2024

Volltextzugriff (PDF)

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT170-CT170

2021

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia

Immunotherapy, 2023-09, Vol.15 (13), p.1029-1044

2023

Volltextzugriff (PDF)

Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial

EClinicalMedicine, 2023-05, Vol.59, p.101952-101952, Article 101952

2023

Volltextzugriff (PDF)

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Nature cancer, 2023-06, Vol.4 (6), p.860-871

2023

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(26)

Publikationsform

Sprache

Englisch
(29)
Chinesisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Life Sciences & Biomedicine
(17)
Oncology
(8)
Respiratory System
(7)
Humans
(6)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(5)
Lung Cancer
(5)
General & Internal Medicine
(4)
Lung Neoplasms - Drug Therapy
(4)
Male
(4)
Aged
(3)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Carcinoma, Non-Small-Cell Lung - Pathology
(3)
Chemotherapy
(3)
China
(3)
Female
(3)
Immunotherapy
(3)
Lung Neoplasms - Pathology
(3)
Machine Learning
(3)
Middle Aged
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

β-arrestin2 is indispensable for the antidepressant effects of fluoxetine via inhibiting astrocytic pyroptosis in chronic mild stress mouse model for depression

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Spatiotemporal reconstruction of global ocean surface pCO2 based on optimized random forest

A method for estimating particulate organic carbon at the sea surface based on geodetector and machine learning

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial

HDAC6 Enhances Endoglin Expression through Deacetylation of Transcription Factor SP1, Potentiating BMP9-Induced Angiogenesis

Novel bismuth ferrite nanopowder prepared by polyethylene glycol-assisted two-step solid-state reaction: Synthesis and magneto-optical properties

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

Spatiotemporal reconstruction of global ocean surface pCO 2 based on optimized random forest

Enzymatic preparation of rice-starch-based surface-modified disordered carbon as an anode for lithium-ion batteries

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring MET exon 14 skipping alterations ( METex14 )

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study

Power Sequencial Data - Forecasting Trend

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)

Pembrolizumab plus chemotherapy for advanced non-small-cell lung cancer without tumor PD-L1 expression in Asia

Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial

Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC

Suchergebnisse filtern